MCID: FLL027
MIFTS: 60

Fallopian Tube Carcinoma malady

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

Aliases & Descriptions for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 52 14 69
Fallopian Tube Cancer 12 50 52 14
Cancer of the Fallopian Tube 12 50
Cancer of Fallopian Tubes 56 29
Fallopian Tube Neoplasms 42 69
Malignant Neoplasm of Fallopian Tube 69
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 56
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Carcinoma of Fallopian Tube 12
Tumor of the Fallopian Tube 12
Neoplasm of Fallopian Tube 12
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 56
Fallopian Tube Ca 12
Tubal Cancer 56

Characteristics:

Orphanet epidemiological data:

56
malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
MeSH 42 D005185
ICD10 33 C57.0
ICD9CM 35 183.2
Orphanet 56 ORPHA180242
UMLS via Orphanet 70 C0153579
ICD10 via Orphanet 34 C57.0

Summaries for Fallopian Tube Carcinoma

NIH Rare Diseases : 50 fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus. it is very rare and accounts for only 1-2% of all gynecologic cancers.  fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor. cancer can begin in any of the different cell types that make up the fallopian tubes. the most common type is called adenocarcinoma (a cancer of cells from glands). leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare.  while some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. for example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon.  women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. the signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. doctors use many tests to diagnose cancer of the fallopian tubes. some of these tests may include: pelvic examination, transvaginal ultrasound, a blood test that measures the tumor marker ca-125, computed tomography (ct or cat) scan, and magnetic resonance imaging (mri). fallopian tube cancer can be best treated when detected early. if the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. the stage of the cancer determines the type of treatment needed. most women will need surgery and some will go on to have chemotherapy and/or radiation therapy. last updated: 5/6/2015

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to fallopian tube adenocarcinoma and fallopian tube carcinosarcoma. An important gene associated with Fallopian Tube Carcinoma is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and GPCR Pathway. The drugs Metformin and Olaparib have been mentioned in the context of this disorder. Affiliated tissues include testes, smooth muscle and colon, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Disease Ontology : 12 A fallopian tube cancer that is located in the fallopian tube.

Wikipedia : 71 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 181)
id Related Disease Score Top Affiliating Genes
1 fallopian tube adenocarcinoma 31.6 ERBB2 ESR1 TP53
2 fallopian tube carcinosarcoma 29.8 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
3 familiar fallopian tube carcinoma 12.0
4 cystinosis, nephropathic 10.3 ERBB2 TP53
5 aortitis 10.3 PGR TP53
6 adult central nervous system mature teratoma 10.3 ERBB2 TP53
7 mouth disease 10.3 ERBB2 PGR
8 pericardium leiomyoma 10.3 PGR TP53
9 breast ductal carcinoma 10.3 PGR TP53
10 mucoepidermoid thyroid carcinoma 10.3 ERBB2 PGR
11 triple-receptor negative breast cancer 10.3 ERBB2 PGR
12 acinar cell carcinoma 10.2 PGR TP53
13 classic congenital mesoblastic nephroma 10.2 PGR TP53
14 skin sarcoma 10.2 ERBB2 PGR
15 porokeratosis 10.2 PGR TP53
16 oro-mandibular-limb hypogenesis syndrome 10.2 ERBB2 TP53
17 aorto-ventricular tunnel 10.2 BRCA1 BRCA2
18 burn scar 10.2 BRCA1 BRCA2
19 lethal congenital contracture syndrome 7 10.2 BRCA1 BRCA2
20 bronchogenic cyst 10.2 BRCA1 BRCA2
21 intestinal neuroendocrine benign tumor 10.2 ERBB2 PGR
22 bronchiectasis oligospermia 10.2 BRCA1 BRCA2
23 bone giant cell tumor 10.2 ERBB2 MYC
24 basaloid squamous cell carcinoma 10.2 ERBB2 PGR
25 infiltrating angiolipoma 10.2 ERBB2 PGR
26 chronic endophthalmitis 10.2 BRCA1 BRCA2
27 seminoma 10.2 PGR TP53
28 acute gonococcal cystitis 10.2 TP53 VEGFA
29 neuropathy, distal hereditary motor, type viib 10.2 BRCA1 BRCA2
30 eccrine sweat gland neoplasm 10.2 BRCA1 BRCA2
31 bladder clear cell adenocarcinoma 10.2 ESR1 TP53
32 ovarian embryonal carcinoma 10.2 PGR TP53
33 ovarian cystadenocarcinoma 10.2 ERBB2 VEGFA
34 frontal sinusitis 10.2 BRCA1 BRCA2
35 hereditary breast ovarian cancer 10.2 ERBB2 ESR1
36 barnicoat baraitser syndrome 10.2 MYC TP53
37 primary hyperoxaluria 10.2 ERBB2 TP53
38 coronary stenosis 10.2 TP53 VEGFA
39 skin angiosarcoma 10.2 MYC PGR
40 bartholin's gland benign neoplasm 10.2 ESR1 PGR
41 cardiovascular organ benign neoplasm 10.2 ESR1 PGR
42 appendix leiomyoma 10.2 ESR1 PGR
43 bronchus adenoma 10.2 ESR1 PGR
44 main bronchus cancer 10.2 PGR VEGFA
45 ovarian benign neoplasm 10.2 ESR1 PGR
46 plexiform neurofibroma 10.2 ESR1 PGR
47 reactive arthritis 10.1 ERBB2 PGR TP53
48 paranasal sinus disease 10.1 ESR1 PGR
49 deafness, autosomal recessive 21 10.1 ESR1 PGR
50 pyloric antrum cancer 10.1 TP53 VEGFA

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):


Ovarian Cancer, Somatic

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:



Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 RAD51D TP53 BRCA1 BRCA2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 MYC RAD51D TP53 BRCA1 BRCA2
3 Synthetic lethal with cisplatin GR00101-A-1 8.96 BRCA1 BRCA2

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 RAD51D VEGFA PGR TP53 MYC ESR1
2 embryo MP:0005380 10.22 VEGFA PGR TP53 MYC ESR1 RAD51D
3 behavior/neurological MP:0005386 10.2 ESR1 VEGFA PGR TP53 MYC BRCA1
4 cardiovascular system MP:0005385 10.19 RAD51D ESR1 VEGFA PGR TP53 MYC
5 homeostasis/metabolism MP:0005376 10.18 RAD51D ESR1 VEGFA PGR TP53 MYC
6 endocrine/exocrine gland MP:0005379 10.16 VEGFA PGR TP53 MYC ESR1 BRCA1
7 growth/size/body region MP:0005378 10.15 MYC RAD51D ESR1 VEGFA TP53 BRCA1
8 limbs/digits/tail MP:0005371 10.13 PGR TP53 MYC RAD51D VEGFA ERBB2
9 digestive/alimentary MP:0005381 10.12 ESR1 VEGFA TP53 MYC BRCA1 ERBB2
10 mortality/aging MP:0010768 10.11 RAD51D ESR1 VEGFA PGR TP53 MYC
11 integument MP:0010771 10.1 VEGFA PGR TP53 MYC ESR1 ERBB2
12 hematopoietic system MP:0005397 10.08 MYC ESR1 VEGFA PGR TP53 BRCA2
13 immune system MP:0005387 10.05 MYC ESR1 VEGFA PGR TP53 BRCA2
14 neoplasm MP:0002006 10.01 VEGFA PGR TP53 MYC ESR1 ERBB2
15 muscle MP:0005369 9.98 ESR1 VEGFA PGR TP53 MYC BRCA1
16 nervous system MP:0003631 9.97 MYC RAD51D ESR1 VEGFA TP53 BRCA1
17 normal MP:0002873 9.86 VEGFA PGR TP53 MYC ESR1 ERBB2
18 reproductive system MP:0005389 9.76 VEGFA PGR TP53 MYC ESR1 BRCA1
19 no phenotypic analysis MP:0003012 9.72 MYC ESR1 VEGFA TP53 PGR
20 respiratory system MP:0005388 9.35 ESR1 VEGFA TP53 BRCA1 ERBB2
21 skeleton MP:0005390 9.23 ESR1 VEGFA PGR TP53 MYC BRCA1

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 14219 4091
2
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
3
Enclomiphene Investigational Phase 4 15690-57-0
4 Clomiphene Phase 4
5 Hypoglycemic Agents Phase 4,Phase 2,Phase 1
6 Zuclomiphene Phase 4
7 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Citrate Nutraceutical Phase 4,Phase 3,Phase 2
9
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
13
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
14
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
15
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
16
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
17
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
18
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
19
Mechlorethamine Approved Phase 2, Phase 3 51-75-2 4033
20
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
21
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
22
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
23
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Alvimopan Approved Phase 3 156053-89-3 5488548
26
Epirubicin Approved Phase 3 56420-45-2 41867
27
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
28
Adenosine Approved, Investigational Phase 3,Phase 2 58-61-7 60961
29
Modafinil Approved, Investigational Phase 3,Phase 2 68693-11-8 4236
30
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
31
Armodafinil Approved, Investigational Phase 3,Phase 2 112111-43-0
32
Succinylcholine Approved Phase 3,Phase 1 306-40-1 5314
33
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
34
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
35
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
37
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
38
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
39
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
40
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
41
Maleic acid Experimental Phase 3,Phase 2,Phase 1 110-16-7 444266
42
Epothilone B Experimental, Investigational Phase 3,Phase 1,Phase 2 152044-54-7
43
Veliparib Investigational Phase 3,Phase 2,Phase 1 912444-00-9 11960529
44 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
45 Alkylating Agents Phase 2, Phase 3, Phase 1
46 glucocorticoids Phase 3,Phase 2,Phase 1
47
protease inhibitors Phase 3,Phase 2,Phase 1
48 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
49 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
50 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 669)
id Name Status NCT ID Phase
1 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
2 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4
3 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4
4 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3
5 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3
6 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Unknown status NCT02328716 Phase 3
7 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
8 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3
9 Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction Unknown status NCT02349763 Phase 3
10 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3
11 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3
12 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
13 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3
14 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3
15 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3
16 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3
17 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
18 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3
19 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3
20 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3
21 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3
22 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3
23 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
24 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3
25 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3
26 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3
27 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3
28 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3
29 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3
30 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3
31 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3
32 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3
33 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3
34 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3
35 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3
36 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3
37 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3
38 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3
39 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
40 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed NCT00976911 Phase 3
41 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Completed NCT00191607 Phase 3
42 Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
43 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Recruiting NCT02631876 Phase 3
44 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT01846611 Phase 3
45 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
46 Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 Recruiting NCT02903004 Phase 3
47 FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer Recruiting NCT02641639 Phase 2, Phase 3
48 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial Recruiting NCT01506856 Phase 2, Phase 3
49 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3
50 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3

Search NIH Clinical Center for Fallopian Tube Carcinoma

Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

id Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 29

Anatomical Context for Fallopian Tube Carcinoma

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

39
Testes, Smooth Muscle, Colon, Ovary, Appendix, Uterus, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Carcinoma:

18
The Fallopian Tube

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show all 46)
id Title Authors Year
1
Evaluation of Short-Term Efficacy of Concurrent Chemoradiotherapy in Primary Fallopian Tube Carcinoma by Diffusion-Weighted Imaging: A Retrospective Study. ( 28423375 )
2017
2
Triple Synchronous Malignancies in Genital Tract; Primary Endometrial, Ovarian and Fallopian Tube Carcinoma: A Case Report. ( 28274004 )
2017
3
Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study. ( 26825825 )
2016
4
Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery. ( 27976970 )
2016
5
Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 26712194 )
2016
6
Response to comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122290 )
2016
7
Associations of Promoter Methylations and mRNA Expressions of MMP-2, MMP-7 and MMP-9 with Primary Fallopian Tube Carcinoma. ( 26785083 )
2016
8
Comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122289 )
2016
9
Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. ( 27307153 )
2016
10
Clinically Occult Primary Fallopian Tube Carcinoma Presenting as a Malignant Pleural Effusion. ( 26646473 )
2015
11
Robotic resection of bulky aorto-caval lymphadenopathy in a patient with serous fallopian tube carcinoma. ( 25449567 )
2015
12
Primary fallopian tube carcinoma: review of MR imaging findings. ( 26150249 )
2015
13
Prognostic Significance of Retroperitoneal Lymphadenectomy, Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Primary Fallopian Tube Carcinoma: A Multicenter Study. ( 25622588 )
2015
14
Primary fallopian tube carcinoma--a retrospective analysis of 66 cases. ( 26050354 )
2015
15
Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma. ( 25846583 )
2015
16
Primary fallopian tube carcinoma: correlation between magnetic resonance and diffuse weighted imaging characteristics and histopathologic findings. ( 25373473 )
2015
17
Magnetic resonance imaging features of fallopian tube carcinoma. ( 25890392 )
2015
18
Metastatic fallopian tube carcinoma presenting as an inguinal hernia. ( 25675933 )
2015
19
Primary fallopian tube carcinoma diagnosed preoperatively by cervical smear. ( 25827704 )
2014
20
Genomic aberrations of BRCA1-mutated fallopian tube carcinomas. ( 24726640 )
2014
21
Primary fallopian tube carcinoma diagnosed with endoscopic ultrasound elastography with fine needle biopsy. ( 25325010 )
2014
22
Primary fallopian tube carcinoma: a case report and mini-review of the literature. ( 25507436 )
2014
23
Primary fallopian tube carcinoma: a case report. ( 25426210 )
2014
24
Clinical and survival analysis of 36 cases of primary fallopian tube carcinoma. ( 25307473 )
2014
25
Co-existence of primary fallopian tube carcinoma and uterine carcinosarcoma. ( 24912001 )
2014
26
Primary fallopian tube carcinoma: a case report and mini-review of the literature. ( 25423713 )
2014
27
Primary fallopian tube carcinoma and ectopic pregnancy: A rare co-occurrence. ( 24411050 )
2013
28
Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features. ( 22038216 )
2011
29
Uncommon manifestations of Endocervical Malignant Mixed Mullerian Tumor with Incidental Bilateral Fallopian Tube Carcinoma. ( 21701666 )
2011
30
Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. ( 19761129 )
2009
31
Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. ( 19898224 )
2009
32
Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier. ( 18207147 )
2008
33
Expression of insulin-like growth factor-1 receptors, Wilm's tumor-1 protein, c-kit and p16 in primary fallopian tube carcinoma in diabetic patients. ( 17972088 )
2008
34
HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. ( 17927588 )
2007
35
Fallopian tube carcinoma: incidental finding during surgery for acute pelvic inflammatory disease--case report. ( 17139993 )
2006
36
Management of bilateral fallopian tube carcinoma coexistent with tuberculous salpingitis. ( 15669995 )
2005
37
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? ( 16319259 )
2005
38
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. ( 15252324 )
2004
39
Tuberculous salpingitis in two of five primary fallopian tube carcinomas. ( 12745571 )
2003
40
Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. ( 12504983 )
2002
41
Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. ( 10629373 )
2000
42
Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. ( 10785486 )
2000
43
Recurrent fallopian tube carcinoma: TP53 mutation and clinical course. ( 10782411 )
2000
44
c-erbB-2 and p53 expression in fallopian tube carcinoma. ( 7773939 )
1995
45
Primary fallopian tube carcinoma with coexistent tuberculous salpingitis: a case report. ( 1556508 )
1992
46
Exfoliative dermatitis: presenting sign of fallopian tube carcinoma. ( 2967452 )
1988

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 85)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 6
2 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 6
3 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 6
4 COSM6932 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 6
5 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 6
6 COSM10659 TP53 endometrium,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 6
7 COSM10663 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 6
8 COSM10648 TP53 endometrium,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 6
9 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 6
10 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 6
11 COSM10656 TP53 endometrium,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 6
12 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 6
13 COSM43596 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 6
14 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 6
15 COSM10863 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.833C>T p.P278L 6
16 COSM10794 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.796G>A p.G266R 6
17 COSM43955 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.514G>A p.V172I 6
18 COSM14049 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1067C>T p.P356L 6
19 COSM14050 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1516G>A p.V506M 6
20 COSM5152 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>T p.R130* 6
21 COSM5215 PTEN endometrium,NS,carcinoma,adenocarcinoma c.356T>A p.V119D 6
22 COSM5165 PTEN endometrium,NS,carcinoma,adenocarcinoma c.519C>T p.R173R 6
23 COSM5033 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>A p.R130Q 6
24 COSM5106 PTEN endometrium,NS,carcinoma,adenocarcinoma c.335T>C p.L112P 6
25 COSM5312 PTEN endometrium,NS,carcinoma,adenocarcinoma c.895G>T p.E299* 6
26 COSM5108 PTEN endometrium,NS,carcinoma,adenocarcinoma c.209T>C p.L70P 6
27 COSM5943 PTEN endometrium,NS,carcinoma,adenocarcinoma c.634+3A>C p.? 6
28 COSM5216 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>T p.R130L 6
29 COSM5039 PTEN endometrium,NS,carcinoma,adenocarcinoma c.518G>A p.R173H 6
30 COSM5115 PTEN endometrium,NS,carcinoma,adenocarcinoma c.155A>G p.D52G 6
31 COSM5212 PTEN endometrium,NS,carcinoma,adenocarcinoma c.319G>T p.D107Y 6
32 COSM5065 PTEN endometrium,NS,carcinoma,adenocarcinoma c.403A>G p.I135V 6
33 COSM5299 PTEN endometrium,NS,carcinoma,adenocarcinoma c.271G>T p.E91* 6
34 COSM5105 PTEN endometrium,NS,carcinoma,adenocarcinoma c.284C>T p.P95L 6
35 COSM5154 PTEN endometrium,NS,carcinoma,adenocarcinoma c.697C>T p.R233* 6
36 COSM5159 PTEN endometrium,NS,carcinoma,adenocarcinoma c.733C>T p.Q245* 6
37 COSM5236 PTEN endometrium,NS,carcinoma,adenocarcinoma c.275A>T p.D92V 6
38 COSM5219 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>G p.R130G 6
39 COSM5276 PTEN endometrium,NS,carcinoma,adenocarcinoma c.386G>T p.G129V 6
40 COSM5235 PTEN endometrium,NS,carcinoma,adenocarcinoma c.218A>T p.E73V 6
41 COSM5048 PTEN endometrium,NS,carcinoma,adenocarcinoma c.196A>G p.K66E 6
42 COSM5107 PTEN endometrium,NS,carcinoma,adenocarcinoma c.71A>G p.D24G 6
43 COSM937333 POLE endometrium,NS,carcinoma,adenocarcinoma c.857C>G p.P286R 6
44 COSM5031089 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>A p.S297Y 6
45 COSM937331 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>T p.S297F 6
46 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 6
47 COSM12597 PIK3CA endometrium,NS,carcinoma,adenocarcinoma c.3145G>C p.G1049R 6
48 COSM13396 MSH6 endometrium,NS,carcinoma,adenocarcinoma c.1723G>T p.D575Y 6
49 COSM520 KRAS endometrium,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 6
50 COSM532 KRAS endometrium,NS,carcinoma,adenocarcinoma c.38G>A p.G13D 6

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 48)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 BRCA1 ERBB2 ESR1 MYC PGR RAD51D
2
Show member pathways
13.52 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
3
Show member pathways
12.68 BRCA1 ESR1 MYC TP53
4
Show member pathways
12.64 ERBB2 ESR1 TP53 VEGFA
5 12.49 BRCA2 ERBB2 MYC TP53 VEGFA
6
Show member pathways
12.48 BRCA1 BRCA2 ESR1 MYC TP53
7 12.45 BRCA1 MYC TP53 VEGFA
8
Show member pathways
12.42 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
9 12.33 BRCA1 ERBB2 MYC TP53 VEGFA
10
Show member pathways
12.24 BRCA1 MYC TP53
11
Show member pathways
12.23 ERBB2 MYC TP53
12
Show member pathways
12.18 ERBB2 MYC TP53
13
Show member pathways
12.15 BRCA1 BRCA2 RAD51D
14
Show member pathways
12.08 BRCA1 ESR1 MYC PGR
15 12.05 MYC TP53 VEGFA
16
Show member pathways
12.05 ERBB2 MYC TP53
17 12.03 ERBB2 ESR1 MYC TP53 VEGFA
18
Show member pathways
12 BRCA1 BRCA2 RAD51D
19 11.88 ESR1 MYC TP53
20 11.87 ERBB2 MYC TP53
21 11.86 MYC TP53 VEGFA
22
Show member pathways
11.83 ERBB2 ESR1 PGR
23
Show member pathways
11.71 BRCA1 BRCA2 TP53
24
Show member pathways
11.7 ERBB2 ESR1 MYC VEGFA
25
Show member pathways
11.7 BRCA2 ERBB2 MYC TP53 VEGFA
26 11.64 BRCA1 ERBB2 TP53
27 11.58 ERBB2 MYC TP53
28 11.57 ERBB2 MYC TP53 VEGFA
29 11.55 BRCA1 ERBB2 MYC
30 11.49 BRCA1 ERBB2 MYC TP53
31 11.43 ESR1 MYC VEGFA
32 11.41 BRCA1 MYC TP53
33 11.38 BRCA1 MYC TP53
34 11.35 ESR1 MYC TP53
35 11.29 BRCA1 BRCA2 ESR1 MYC TP53 VEGFA
36 11.27 BRCA2 ESR1 MYC
37 11.27 BRCA1 MYC TP53 VEGFA
38 11.25 ESR1 TP53
39 11.21 MYC TP53
40 11.2 BRCA1 TP53
41 11.18 BRCA1 TP53
42 11.15 BRCA1 TP53
43 11.14 MYC TP53
44 11.13 ESR1 MYC
45 11.12 MYC TP53
46 11.01 MYC TP53
47
Show member pathways
11.01 MYC TP53
48 10.93 BRCA1 TP53

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.8 BRCA1 BRCA2 ESR1 MYC PGR RAD51D
2 cytoplasm GO:0005737 9.61 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
3 replication fork GO:0005657 9.32 RAD51D TP53
4 lateral element GO:0000800 9.16 BRCA1 BRCA2
5 protein complex GO:0043234 9.02 BRCA1 BRCA2 ESR1 MYC TP53

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 BRCA1 BRCA2 ESR1 MYC TP53
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.91 BRCA1 ESR1 MYC PGR TP53 VEGFA
3 regulation of transcription from RNA polymerase II promoter GO:0006357 9.88 BRCA1 ERBB2 ESR1 MYC VEGFA
4 cell proliferation GO:0008283 9.87 BRCA2 ERBB2 MYC TP53
5 protein deubiquitination GO:0016579 9.84 BRCA1 ESR1 MYC TP53
6 regulation of apoptotic process GO:0042981 9.82 BRCA1 ESR1 TP53
7 cellular response to DNA damage stimulus GO:0006974 9.8 BRCA1 BRCA2 MYC RAD51D TP53
8 negative regulation of gene expression GO:0010629 9.78 ESR1 MYC PGR
9 DNA recombination GO:0006310 9.75 BRCA1 BRCA2 RAD51D
10 cellular response to hypoxia GO:0071456 9.73 MYC TP53 VEGFA
11 double-strand break repair via homologous recombination GO:0000724 9.72 BRCA1 BRCA2 RAD51D
12 positive regulation of epithelial cell proliferation GO:0050679 9.7 ERBB2 MYC VEGFA
13 negative regulation of fibroblast proliferation GO:0048147 9.63 MYC TP53
14 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.63 BRCA2 TP53
15 nucleotide-excision repair GO:0006289 9.63 BRCA2 RAD51D TP53
16 cell aging GO:0007569 9.62 BRCA2 TP53
17 positive regulation of mesenchymal cell proliferation GO:0002053 9.62 MYC VEGFA
18 positive regulation of cell cycle arrest GO:0071158 9.61 BRCA1 TP53
19 response to X-ray GO:0010165 9.6 BRCA2 TP53
20 mammary gland alveolus development GO:0060749 9.59 ESR1 VEGFA
21 cellular response to estrogen stimulus GO:0071391 9.58 ESR1 MYC
22 DNA synthesis involved in DNA repair GO:0000731 9.54 BRCA1 BRCA2 RAD51D
23 response to gamma radiation GO:0010332 9.5 BRCA2 MYC TP53
24 chordate embryonic development GO:0043009 9.49 BRCA1 BRCA2
25 chromosome organization GO:0051276 9.43 BRCA2 MYC RAD51D
26 positive regulation of gene expression GO:0010628 9.35 BRCA1 ERBB2 MYC TP53 VEGFA
27 strand displacement GO:0000732 9.33 BRCA1 BRCA2 RAD51D
28 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53
29 transcription, DNA-templated GO:0006351 10.11 BRCA1 ERBB2 ESR1 MYC PGR TP53

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.46 ERBB2 MYC TP53 VEGFA
2 steroid binding GO:0005496 9.32 ESR1 PGR
3 gamma-tubulin binding GO:0043015 9.26 BRCA2 RAD51D
4 enzyme binding GO:0019899 9.26 BRCA1 ESR1 PGR TP53
5 DNA binding GO:0003677 9.17 BRCA1 BRCA2 ESR1 MYC PGR RAD51D

Sources for Fallopian Tube Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....